Translate Bio, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|
| Revenue | $4.7M | $1.5M | $238,000 | — |
| Operating income | −$14.8M | −$34.2M | −$22.4M | −$14.9M |
| Net income | −$14.3M | −$33.2M | −$21.2M | −$14.0M |
| Total assets | $889.9M | $336.2M | $287.7M | $198.5M |
| Total liabilities | $533.2M | $182.7M | $162.4M | $99.2M |
| Equity | $356.8M | $153.5M | $125.3M | −$93.5M |
| EPS (diluted) | $-0.24 | — | — | — |
| Shares out. | 60.0M | 45.3M | 45.1M | 9.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −317.8%
- Net margin
- −306.9%
- Return on equity
- −4.0%
- Return on assets
- −1.6%
- Return on capital (ROCE)
- −1.9%
- Liabilities / assets
- 59.9%
- Debt / equity
- 1.49×
- Book value / share
- $5.94
- Revenue growth (YoY)
- 215.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- 3.47safe
- Accruals / assets
- −28.2%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsSep 14, 2021
- Entered a material agreement · Other material eventAug 3, 2021
- Director / officer change · Shareholder voteJun 16, 2021
- Director / officer changeApr 20, 2021
- Director / officer changeMar 23, 2021
- Results of operationsFeb 25, 2021
- Director / officer changeDec 28, 2020
- Director / officer changeDec 22, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BSep 24, 2021
- EFFECTSep 21, 2021
- EFFECTSep 21, 2021
- 4/AFORM 4/ASep 16, 2021
- SC 13D/ANONESep 16, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4/AFORM 4/A SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
- 4FORM 4 SUBMISSIONSep 14, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.